Pfizer's Strategic Moves Amid Trump's Tariff Relief Plans

Pfizer has struck a significant deal with President Donald Trump, agreeing to lower prescription drug prices under the Medicaid program. This decision comes in exchange for tariff relief, aligning U.S. drug prices with those in other developed countries. The deal is expected to encourage similar moves by other pharmaceutical companies.

The agreement between Pfizer and Trump has propelled healthcare stocks in the U.S. and Europe. Industry experts view this arrangement as a positive development amid considerable uncertainty over drug prices and policies. The clarity offered by this deal is a relief for the sector, which faced a turbulent year.

Meanwhile, Indivior, a UK-based pharmaceutical company, announced plans to relocate its corporate domicile to the U.S., aiming for better capital markets. This move reflects a growing trend of firms shifting operations to the U.S. for enhanced investor confidence and financial prospects.

(With inputs from agencies.)